Depressive Episode
40
7
7
20
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.0%
6 terminated out of 40 trials
76.9%
-9.6% vs benchmark
8%
3 trials in Phase 3/4
40%
8 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (40)
Role Of Non-Specific Effects in The Treatment of Depression With Esketamine
Chronotherapy for Depressive Episodes
Behavioral Activation Teletherapy to Increase Physical Activity
Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression
Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS
Improving Treatment for Depression in General Practice Using a Step-by-Step Care Plan.
Mental Health Associations With Vitiligo
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
Esketamine vs ECT for Acute Suicidality
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
Youth Depression and Suicide Research Network
OSU6162 as add-on in SSRI/SNRI-resistant Depression
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Characterisation of Fundamental Decision Making in People Suffering From a Characterised Depressive Episode
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder
RCT for Electroconvulsive Treatment Followed by Cognitive Control Training
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
Predictive Value of the DD4 Questionnaire on Depressive Relapse After Hospitalization
Self-guided Treatment for Adolescents Navigating Depression
Electroconvulsive Treatment Followed by Cognitive Control Training